Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

Next Previous
Trial Profile

A Phase 1b Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Firmonertinib (Primary)
  • Indications Brain metastases; Non-small cell lung cancer
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms FURTHER
  • Sponsors ArriVent Biopharma

Most Recent Events

  • 03 Mar 2025 According to an ArriVent Biopharma media release, in September 2024 company presented interim results of phase 1b presented at the 2024 World Conference on Lung Cancer.
  • 14 Nov 2024 According to ArriVent Biopharma media release, ArriVent expects to provide an update on EGFR PACC plans in the first half of 2025.
  • 12 Aug 2024 According to an ArriVent Biopharma media release, company will present interim first-line monotherapy data from this study to be presented as a presidential symposium presentation at the 2024 World Conference on Lung Cancer (WCLC).Also the company plans to host a virtual webinar event on the Phase 1b firmonertinib EGFR PACC data on Sep 9, 2024 at 4:30pm

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top